Dechra Pharmaceuticals PLC Additional Listing (1283L)
September 29 2016 - 1:01AM
UK Regulatory
TIDMDPH
RNS Number : 1283L
Dechra Pharmaceuticals PLC
29 September 2016
29 September 2016
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application has been made to the Financial Conduct Authority
and the London Stock Exchange for a total of 140,000 ordinary
shares of 1 pence each (the "Shares") to be admitted to the
Official List.
These Shares are being reserved under a block listing and will
be issued pursuant to the following scheme:
Scheme Shares
Long Term Incentive Plan 140,000
These Shares will rank pari passu with the Company's existing
shares in issue. It is expected that admission will become
effective on 30 September 2016.
For further information
For further information, please contact:
Dechra Pharmaceuticals PLC
Suzana Cross, Company Secretary
Telephone number: +44 (00 1606 814730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. The majority of Dechra's
products are focused on key therapeutic categories where we have
leading market positions, and many of our products are used to
treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor
products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra
and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSLLFVEAIITFIR
(END) Dow Jones Newswires
September 29, 2016 02:01 ET (06:01 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2023 to Apr 2024